Shares of Genmab (NASDAQ:GMAB) climbed 7% following the announcement of its fourth-quarter earnings, which revealed a net ...

Genmab (GMAB) and Sonic Automotive (SAH) are climbing 5% and 3%, respectively, after investment banks issued favorable notes ...

Exane analyst Victor Floch upgraded Genmab (NASDAQ:GMAB) A/S shares from Underperform to Neutral, adjusting the price target ...

Leerink analyst Jonathan Chang upgraded Genmab (GMAB) to Outperform from Market Perform with a $27 price target, citing a longer-term view ...

Global net sales of EPKINLY/TEPKINLY were USD 281 million in 2024. Net product sales in the U.S. and Japan by Genmab were DKK 1,743 million in 2024 compared to DKK 421 million in 2023. EPKINLY was ...

BNP Paribas upgraded shares of Genmab A/S (NASDAQ:GMAB – Free Report) from a strong sell rating to a hold rating in a report issued on Tuesday morning,Zacks.com reports. GMAB has been the subject of a ...

In this article, we are going to take a look at where Genmab A/S (NASDAQ:GMAB) stands against the other healthcare stocks. McKinsey reported that, since 2019, the US healthcare industry witnessed ...

COPENHAGEN, Denmark - Genmab A/S (NASDAQ:GMAB), a biotechnology company specializing in pharmaceutical preparations with a market capitalization of $12.2 billion and an impressive 95% gross profit ...

Genmab AS (GMAB) reports a 31% revenue increase and outlines strategic plans for 2025 amidst competitive market challenges.

COPENHAGEN, Denmark; February 12, 2025 – Genmab A/S (Nasdaq: GMAB) announced today the publication of its Annual Report for 2024. Below is a summary of business progress in 2024, financial ...

Genmab will hold a conference call to discuss the full year results for 2024 today, February 12, 2025, at 6:00 pm CET, 5:00 pm GMT, 12:00 pm EST. To join the call please use the below registration ...